Boehringer Ingelheim and Eli Lilly announced an academic collaboration with the University of Oxford to investigate the effects of Jardiance on the progression of kidney disease and the occurrence of cardiovascular death, in adults with established chronic kidney disease with and without diabetes.
Bristol-Myers Squibb will deploy Sirenas’ drug discovery platform against certain undisclosed challenging therapeutic targets to identify potential drug candidates.
Philanthropist Bill Gates’ fund is aimed at wiping out the disease in seven of the region’s countries and the Dominican Republic.
BioSpace present its NextGen Bio “Class of 2018,” a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
Array BioPharma spun off some intellectual property and equipment into a new company, Yarra Therapeutics.
Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy
Biogen and Ionis Pharmaceuticals announced that they entered into a new collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of spinal muscular atrophy (SMA).
Shares of Zymeworks shot up more than 33 percent after the company announced a licensing deal with Janssen Biotech to develop six bispecific antibodies.
Boehringer Ingelheim struck a deal targeting liver disease with MiNA Therapeutics.
Icyte Corporation struck a deal worth up to $900 million with Maryland-based MacroGenics Inc. for that company’s investigational PD-1 inhibitor.
Two weeks after securing more than $46 million in financing, Visterra struck a deal worth up to $1 billion with startup Vir Biotechnology.
Eli Lilly signed an R&D collaboration deal with CureVac that could total up to $1.8 billion to develop and commercialize up to five possible cancer vaccines.
Through a strategic collaboration deal with Roche, Warp Drive Bio will use its Genome Mining Platform to investigate potential antibiotics for drug-resistant Gram-negative bacteria.
KalVista Pharmaceuticals Inc. inked a collaboration deal with Merck & Co. for potential therapeutic treatments for diabetic macular edema.
Takeda Pharmaceutical announced a collaboration to help transform novel Stanford University research into next-generation treatments for diseases.
Sutro Biopharma and Celgene modified their 2014 immuno-oncology collaboration revolving around four programs that are in preclinical development.
Two pharma giants are combining forces to take on multiple cancers in a deal worth up to $8.5 billion.
Eli Lilly and Nektar Therapeutics announced a strategic collaboration to co-develop NKTR-358, a novel immunological therapy discovered by Nektar.
Corning announced at President Trump’s “Made in America” event that the company planned to create 1,000 new high-tech jobs in the U.S.
Novo Nordisk and Glooko advance their digital health collaboration with launch of unique integrated app for improved diabetes management
Novo Nordisk and Glooko announced that the new Cornerstones4Care Powered by Glooko app (C4C app) is now available to help people more effectively manage their diabetes.
Genentech is returning the rights to NewLink Genetics’ IDO inhibitor GDC-0919 (navoximod). However, the overall research collaboration the two companies have to identify next-generation IDO/TDO (tryptophan 2,3-dioxygenase) inhibitors will continue.